Article
Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: does standardisation matter?
3rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria.
Thrombosis and Haemostasis (impact factor:
5.04).
03/2012;
107(3):538-44.
DOI:10.1160/TH11-09-0623
pp.538-44
Source: PubMed
-
Citations (0)
-
Cited In (0)
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
48-61% platelet reactivity index
62 individuals
90 minutes
clinical trials
day 0
day 1
day 2
geometric
lag time
maximum difference
measure thienopyridine effects
median FI
median fluorescence intensities
processed samples
recommended time-span
reported cut-offs
reported optimal cut-offs
Time-to-assay
Tolerably stable results
vasodilator-stimulated phosphoprotein-phosphorylation